The EuroSIDA study is a prospective observational cohort study of more than 16.505 patients followed in 103 hospitals in 32 European countries plus Israel and Argentina. The main objective of the study is to assess the impact of antiretroviral drugs on the outcome of the general population of HIV-infected patients living in Europe.
Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773) and the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord n° 260694) programmes. Current support also includes unrestricted grants by Gilead, Pfizer, BMS, Merck and Co. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787).
Updated: 23 May 2011